Drugs / paclitaxel liposomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06578299 | Aug 2024 → Mar 2026 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07125391 Background | Jun 2025 → Aug 2026 overdue | ovarian carcinoma | Bai-Rong Xia | Recruiting | No outcome recorded |
| Phase 2 | NCT06424899 Background | May 2024 → May 2027 expected | non-small cell lung carcinoma | Zeng Jian | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | paclitaxel liposomes | “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗2“Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously” NCT06578299 ↗ “paclitaxel liposomes (135-175 mg/m² on day 1, every 3 weeks)” NCT07125391 ↗ |
| Route | Intravenous | “Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously” NCT06578299 ↗ |